Eli Lilly (LLY) is back in focus for investors after its recent share performance, with the stock closing at $1,127.69 and sitting within a large pharmaceutical portfolio that spans cardiometabolic, oncology, immunology, and neuroscience therapies.

The recent 0.93% 1 day share price return has added to Eli Lilly’s strong momentum, with a 30 day share price return of 5.91% and a 1 year total shareholder return of 42.83%.

If Eli Lilly’s run has you thinking about what else is moving in health related AI, this is a good moment to scan 39 healthcare AI stocks

With Eli Lilly now valued near US$1t and trading not far from analyst targets, the key question is whether current prices still leave a margin of safety or if the stock already reflects much of its future growth potential.

Most Popular Narrative: 23.7% Undervalued

According to the most followed narrative on Eli Lilly, a fair value of $1,477.03 sits well above the last close at $1,127.69. This frames the recent rally in a different light.

You are buying a business already growing at 25% annually, with its most important new drug not yet approved and not yet reflected in any revenue number, at a price that a conservative model says is 27 to 32% below fair value. The pricing headwinds are real, but they are happening to a company with manufacturing scale, regulatory depth, and a next-generation compound that has already beaten the highest analyst expectations in Phase 3. That is the story. Everything after this is just watching the trial readouts come in.

Curious what sits behind that fair value for Eli Lilly? The narrative leans on firm revenue expansion assumptions, resilient margins, and a future earnings multiple usually reserved for market leaders.

Result: Fair Value of $1,477.03 (UNDERVALUED)

However, this Eli Lilly narrative can break if pricing pressure on obesity drugs accelerates or if key late stage trial results fail to match current expectations.

Another View on Eli Lilly’s Valuation

The user narrative argues Eli Lilly is about 23.7% undervalued, but the current P/E of 39.8x tells a different story. That multiple is far above the US pharmaceuticals industry at 14.7x, the peer average at 24.1x, and even the 35.6x fair ratio our model suggests the market could move toward.

This gap implies valuation risk if sentiment cools or earnings do not keep pace with expectations, even if the long term growth story plays out. How comfortable are you paying a premium today for a stock already priced above its own fair ratio multiple?

Next Steps

Conflicted by the mix of enthusiasm and caution around Eli Lilly? Take a closer look at the underlying data today and form your own stance with the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Eli Lilly?

If Eli Lilly has sharpened your focus on quality, do not stop here. Use the Simply Wall Street Screener to uncover fresh opportunities that fit your style.

• Zero in on quality at a discount by scanning 43 high quality undervalued stocks that pair solid fundamentals with attractive pricing.
• Strengthen your portfolio’s foundation by reviewing the solid balance sheet and fundamentals stocks screener (48 results) for businesses with resilient financial positions.
• Get ahead of the crowd by checking the screener containing 19 high quality undiscovered gems before these opportunities become widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.